Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Receivables (2019 - 2025)

Historic Change in Receivables for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $4.3 million.

  • C4 Therapeutics' Change in Receivables fell 5268.15% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 13859.99%. This contributed to the annual value of -$8.7 million for FY2024, which is 18421.61% down from last year.
  • Latest data reveals that C4 Therapeutics reported Change in Receivables of $4.3 million as of Q3 2025, which was down 5268.15% from -$5.8 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Change in Receivables registered a high of $11.3 million during Q4 2023, and its lowest value of -$12.4 million during Q2 2024.
  • For the 5-year period, C4 Therapeutics' Change in Receivables averaged around $108315.8, with its median value being -$63000.0 (2022).
  • As far as peak fluctuations go, C4 Therapeutics' Change in Receivables surged by 7543333.33% in 2023, and later tumbled by 258620.0% in 2024.
  • Over the past 5 years, C4 Therapeutics' Change in Receivables (Quarter) stood at $871000.0 in 2021, then crashed by 101.72% to -$15000.0 in 2022, then soared by 75433.33% to $11.3 million in 2023, then tumbled by 164.06% to -$7.2 million in 2024, then soared by 159.97% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, -$5.8 million for Q2 2025, and $4.9 million during Q1 2025.